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RESEARCH ARTICLE
OBJECTIVES: The aim was to develop and validate a LC-MS/MS assay to 
determine antiretrovirals in human plasma for routine therapeutic drug mon-
itoring.
METHODS: The selectivity, sensitivity, linearity, accuracy, precision, recovery, 
matrix effect, stability and dilution integrity and carry-over were validated ac-
cording to EMA and FDA standards.
RESULTS: For accuracy and precision, the highest overall bias was 11.3% 
at LLOQ of both lopinavir and saquinavir. The highest overall CV was 15.6% 
at the LLOQ of darunavir. Storage stability at 4°C, 20–25°C and 10°C had a 
maximum CV of 13.2% at low QC level (0.2 mg/L) for saquinavir. Freeze-thaw 
stability had a maximum overall bias of 7.4% at low QC level (0.8 mg/L) for 
tipranavir. Selectivity and specificity showed no interfering peaks of more than 
20% of the LLOQ.
CONCLUSIONS: The bioanalytical method is suitable for both TDM in stan-
dard care and clinical studies.
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The treatment of Human Immunodeficiency Virus (HIV) has improved significantly 
over the last three decades. This improvement was entirely due to the broad intro-
duction of antiretroviral (ARV) drugs in a combined treatment regimen (cART) [1]. 
With the advent of cART the mortality and morbidity associated with HIV-1 infection 
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and acquired immunodeficiency syndrome (AIDS) sharply decreased [2]. ARV drugs are 
designed to intervene in the HIV replicative cycle, which eventually results in an HIV ri-
bonucleic acid (RNA) load decrease and subsequently, the recovery of the host immune 
system. Currently, 25 ARV drugs have been approved for the treatment of HIV by the Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) [3]. These 
drugs are divided in six classes, each class representing a target in the HIV life cycle: 
Nucleoside Reverse Transcriptase Inhibitors (NRTI), Nonnucleoside Reverse Transcrip-
tase Inhibitors (NNRTI), Protease Inhibitors (PI), Fusion Inhibitors (FI), Entry Inhibitors and 
integrase strand transfer inhibitors (INI) [3].
In order to optimize treatment outcome and to prevent drug resistance, therapeutic drug 
monitoring (TDM) is recommended in cases of: drug-drug interaction; renal or hepatic 
morbidity; pregnancy; administration of drug doses not commonly used; virologic failure; 
suspicion of nonadherence and adverse events [4]. In order to be eligible for TDM a 
correlation should exist between drug concentrations and effect or adverse effects; or, 
a drug should have large inter-individual pharmacokinetic variability; or a narrow thera-
peutic index [5]. In daily practice at this point NNRTIs, PIs and INIs qualify for TDM [5-7]. 
Previously, several assays have been published describing the simultaneous determi-
nation of ARV drugs for TDM [8-11]. The analytical methods described often used UV 
detection or included an extensive sample preparation such as liquid-liquid extraction. 
These methods are time-consuming and incur high costs. Lliquid chromatography (LC) 
tandem mass spectrometry (MS) is considered to be the most important analytical tech-
nique which is superior to UV detection due to its specificity [12]. Further, using a stable 
isotope internal standard (IS) for LC tandem MS is highly recommended as it corrects 
for injection and ionization variability [13]. A stable isotope IS will compensate for these 
deviations and ensures a robust, high-throughput assay [13].     
The aim of this study was to develop and validate a bioanalytical assay to determine both 
older and new PIs and NNRTIs, and two INIs with a simple sample preparation and using 
stable isotope IS followed by LC-MS/MS analysis in human plasma as this approach is 




The following ARVs were included in the method: amprenavir, atazanavir, darunavir, 
dolutegravir, etravirine, indinavir, lopinavir, nelfinavir, nelfinavir-M8, nevirapine, raltegra-














2H4]-tipranavir. The ARVs and IS used (Figure 1), were 
purchased from Alsachim (Illkirch, Graffenstaden, France), except for nelfinavir-M8 which 
was purchased from Pfizer Inc. (New York, Unites States of America). Acetonitrile for LC-
MS/MS was purchased from BioSolve (Valkenswaard, The Netherlands). The chemicals 
used, including methanol and trifluoroacetic acid, were of high-pressure liquid chroma-
tography (HPLC) or analytical grade and were purchased from VWR (Amsterdam, The 
Netherlands). Purified water was obtained from a Milli-Q water purifying system (Millipore 
Corporation, Billerica, MA, USA).
Both pooled human serum samples and pooled human plasma samples with ethylene 
diamine tetraacetic acid (EDTA) as anticoagulant (Becton Dickinson Vacutainer®, K2E 
7.2 mg) were made available in accordance with the standard operating procedures of 
our medical center.
One milligram of each stable isotope IS was added to methanol to a concentration of 1 
g/L and stored at -80°C. The precipitation reagent consisted of a mixture of methanol Li-
chrosolv, acetonitrile (4:21, v/v) and IS. Twenty-five microliters per IS was standard spiked 
Figure 1. Chemical structures of  the analytesand stable isotope internal standards used in the current bioanalytical method.
1 = Amprenavir, 2 = [2H4]-amprenavir, 3 = Atazanavir, 4 = [
2H6]-atazanavir, 5 = Darunavir, 6 = [
13C6]-darunavir, 7 = Dolutegravir, 
8 = [13C, 2H5]-dolutegravir, 9 = Etravirine, 10 = [
13C6]-etravirine, 11 = Indinavir (sulphate), 12 = [
13C4,
15N]-indinavir, 13 = Lopinavir, 
14 = [2H8]-lopinavir, 15 = Nelfinavir (mesylate monohydrate), 16 = [
2H3]-250nelfinavir, 17 = Nevirapine, 18 = [
2H4]-nevirapine, 19 = 
Raltegravir, 20 = [2H6]-raltegravir, 21 = Ritonavir, 22 = [
13C, 2H3]-ritonavir, 23 = Saquinavir (mesylate), 24 = [
2H9]-251saquinavir, 25 
= Tipranavir, 26 = [2H4]-tipranavir, 27 = Nelfinavir-M8
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directly in 250 mL precipitation reagent. To 10 µL of each sample, a volume of 750 µL 
of precipitation reagents combined with the IS was added to a vial. The samples were 
vortexed for 1 min. The vials were centrifuged for 5 min at 9500g. Ten microliters of the 
upper layer was injected into the LC-MS/MS. 
The analysis was performed on a triple-quadrupole LC-MS/MS (Thermo Scientific, San 
Jose, CA, USA) with an MS Pump Plus (Finnigan Surveyor) and autosampler Plus (Fin-
nigan Surveyor). The mass spectrometer was a triple-stage quadrupole Quantum Access 
Max mass spectrometer. The autosampler temperature was set at 10°C. Liquid chromato-
graphic separation was performed on a HyPURITY C18 analytical column (50 by 2.1 
mm, 3 µm particle size; Thermo Scientific, Interscience, Breda, The Netherlands), and 
the temperature was set at 20°C. The mobile phase had a flow rate of 0.5 mL/min and 
consisted of purified water, acetonitrile, and an aqueous buffer (containing ammonium 
acetate [5 g/L], acetic acid [35 mL/L of water], and trifluoroacetic acid [2 mL/L of water]. 
The method had a run time of 2.9 min and chromatographic separation was performed 
by means of an elution gradient shown in Table 1. Peak area ratios of the ARVs and their 
IS were used to calculate concentrations.
The MS was operating in positive electrospray ionization mode and selected reaction 
monitoring (SRM) mode with a positive spray voltage of 5,000V, a capillary temperature 
of 350°C, a vaporizer temperature of 150°C and a sheath gas pressure and auxiliary 
pressure of 60 and 10 arbitrary units, respectively. High-purity argon was used for both 
the source and collision gas flows and high-purity nitrogen for the sheath gas. The mass 
transitions used in ARV drug quantification and the detail mass spectrometry conditions 
are demonstrated in Table 2. A scan width of 0.5 m/z was used for all components. Peak 
area integration for all components was calculated by Xcalibur software version 2.0.7 
(Thermo Fisher, San Jose, CA, USA).
Method validation
The analytical method was validated in accordance with the guidance for Industry of the 
FDA and the EMA guidelines [14,5]. For the validation of the assay the selectivity, sensi-
tivity, linearity, accuracy, precision, recovery, matrix effect, stability and dilution integrity 
were determined.  
For all components separate stock solutions were made in a concentration of 10 g/L, with 
the exception of tipranavir; for this drug a stock solution of 20 g/L was made. All stock 
solutions were diluted to 500 mg/L, except for the stock solution of tipranavir that was di-
luted to 2 g/L. Dimethylsulfoxide (DMSO) was used as solvent for dilution. Subsequently 
1, 2, 5, 10, 25, 50, 100, 150 and 200 µL of each diluted stock solution was spiked to 5 
mL EDTA plasma, resulting in a final composition of 4% organic solvent in the calibration 
Table 1. Gradient elution.
Time (min) A (%) B (%) C (%)
0.00 5 90 5
0.40 5 90 5
0.41 5 45 50
1.80 5 37.5 57.5
1.81 5 0 95
2.50 5 0 95
2.51 5 90 5
2.90 5 90 5
A: aqueous buffer, B: purified water, C: acetonitrile.
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standards. The analysis for linearity was conducted in 5 replicates per concentration. 
The selection of the assay range was based on the utilization for TDM in daily practice. 
The calibration standards, blanks, and quality control (QC) samples were fully thawed at 
room temperature. The criteria used for the selection of the QC concentration levels were 
based on FDA and EMA guidelines [14,15], LOW was 2 or 3 times the LLOQ; MED was at 
40% and HIGH was at 80%. QC samples and calibration standards were stored at -20°C. 
QC samples with 4 different concentrations of each ARV were used. The concentrations 
and number of samples used for the calibration curves in combination with the concen-
trations used for the QC samples per component are shown in Table 3. 
Table 2. Mass transitions and detail mass spectrometry conditions.








Nevirapine NNRTI 267.1 226.1 25 1.30
[2H4]-Nevirapine 271.1 230.1 26 1.30
Indinavir PI 614.3 364.1 29 1.45
[13C4,
15N]-Indinavir 619.3 470.2 23 1.45
Dolutegravir INI 420.1 277.0 26 1.50
[13C, 2H5]-Dolutegravir 426.1 277.0 27 1.50
Nelfinavir-M8 PI 584.4 330.0 33 1.50
Nelfinavir 568.3 467.2 26 1.85
[2H3]-Nelfinavir 571.3 470.2 28 1.85
Raltegravir INI 445.1 360.9 17 1.55
[2H6]-Raltegravir 451.2 367.1 17 1.55
Saquinavir PI 671.3 433.2 42 1.60
[2H9]-Saquinavir 680.4 433.2 42 1.60
Amprenavir PI 506.2 418.1 12 1.75
[2H4]-Amprenavir 510.2 418.2 13 1.75
Darunavir PI 548.2 392.1 14 1.75
[13C6]-Darunavir 554.3 398.1 13 1.75
Atazanavir PI 705.4 335.1 28 2.00
[2H6]-Atazanavir 711.4 338.1 28 2.00
Ritonavir PI 721.2 197.0 39 2.20
[13C,3H5]-Ritonavir 725.3 201.0 38 2.20
Lopinavir PI 629.3 429.2 22 2.30
[2H8]-Lopinavir 637.4 429.2 22 2.30
Etravirine NNRTI 435.0 303.9 37 2.50
[13C6]-Etravirine 441.1 310.0 37 2.50
Tipranavir PI 603.2 333.0 29 2.60
[4H4]-Tipranavir 607.2 334.1 29 2.60
NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor, PI: Protease Inhibitor, INI: Intergrase Inhibitor
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For selectivity, 6 pooled human plasma samples were examined for interference and 
their responses were compared with those of the LLOQ samples. Over 3 days, each 
day a single calibration curve in plasma was analysed and accuracy was measured by 
evaluation of five determinations per QC sample on three consecutive days. Precision 
was divided into within-run and between-run values using the same method as used for 
the accuracy. The coefficient of variation (CV) for the LLOQ was maximized at 20% de-
viation and the CV for the other QC samples should not exceed 15%. The recovery was 
determined on three levels (LOW, MED, and HIGH) and was done in five replicates. The 
stabilities of the ARVs were tested for storage stability and freeze-thaw stability. Storage 
stability of the ARVs was examined by storing QC samples at room temperature (20°C to 
25°C) in a refrigerator at 4°C and after sample preparation in the autosampler at 10°C, 
all for 7 days. Stability was also tested using five freeze-thaw cycles at -20°C. All stability 
tests were done using two different QC levels (LOW and HIGH) in five determinations 
per concentration. The FDA does not describe a maximum CV requirement for stability, 
therefore a maximum CV of 15% was used for the current method in accordance with the 
EMA guidelines [14]. In order to determine potential differences between the analysis of 
ARVs in human plasma and in human serum, a matrix comparison was performed. Since 
protein precipitation was the single required sample preparation step in this method, rela-
tive recovery was measured by comparing the ratios of integrated peak area of the ARVs 
and the corresponding IS of the QC samples processed with the average peak area 
of the recovery samples. Recovery samples (low, med, and high) were post-extraction 
blank samples spiked at the same concentrations as the QC samples. To determine the 
dilution integrity, on three consecutive days, for each ARV drug a sample was diluted 10 
times and then prepared in five replicates. To determine the carry-over a blank sample 
Table 3. Concentrations of  calibration standards and QC samples. 
Component Calibration curves QC samples mg/L
Number of  
samples













9 0.1, 0.2, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 0.1 0.2 8.0 16.0
Dolutegravir
Raltegravir 6 0.2, 0.5, 1.0, 2.5, 5.0, 10.0 0.2 0.5 4.0 8.0
Tipranavir 9 0.4, 0.8, 2.0, 4.0, 10.0, 20.0, 40.0, 60.0, 80.0 0.4 0.8 32.0 64.0
QC: quality control, LLOQ: lower limit of  quantitation
DASKAPAN A et al.
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Figure 2. Chromatograms of  the included antiretrovirals and the corresponding stable isotope internal standards at the LLOQ and 
blank plasma.
DASKAPAN A et al.
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was analysed after analysing the highest calibration standard per component. 
Clinical application 
After the method was validated and approved it was used for TDM in standard care. 
For use in daily practice blood was collected in a EDTA blood collection tube. Whole 
blood was centrifuged with 9500 x g for 5 min and a minimum of 0.500 mL plasma was 
transferred to a vial and stored until analysis in a – 80°C refrigerator. For analysis 10 µL 
of plasma was transferred to a vial and 750 µL of precipitation reagent was added. The 
sample was vortexed for 1 min and subsequently centrifuged for 5 min at 9500 x g. Ten 
microliters of the upper layer was injected into the LC-MS/MS. One calibration curve was 
used containing all 14 components. The performance of the assay is routinely evaluated 
by participation in the international quality control program of ARV drugs of the Asso-
ciation for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology 
















































































































































Temp: temperature, AS stab: autosampler stability, F/T 5: stability of  5freeze and thaw cycles
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(KKGT) [7,16].
Statistics 
Results were analysed using one-way analysis of variance (ANOVA) in validated Excel 
sheets (Microsoft, Redmond, WA).
RESULTS 
Method development
For this bioanalytical method several points of consideration were identified regarding 
mobile- and stationary phase, sample pre-treatment, MS parameters and usability in dai-
ly clinical practice. Earlier studies showed adequate liquid-liquid extraction [8,10,17], 
however simple sample precipitation was preferred for the current method since it is less 
time-consuming and less expensive [18]. The precipitation reagent has been used for 
many other bioanalytical methods in the current composition, among others for the deter-
mination of azole antifungals and ertapenem [19,20], and therefore was found to be suit-
able for this bioanalytical method. In order to obtain adequate retention of the highly polar 
ARVs an analytical column with high stability under aqueous mobile phase conditions 
was required. The HyPURITY C18 analytical column has a good polar retention capacity 
and showed adequate peak shape, retention time and has been extensively used in our 
daily routine making it a sufficient column for bioanalytical determinations in daily practice 
in combination with the mobile phase used in a stepwise gradient as demonstrated in 
Table 1. Since the particle diameter of the HyPURITY C18 analytical column was 3 µm the 
flow rate of the mobile phase was set at 0.5 mL/min in order to ensure optimized resolution 
and retention time (Figure 2). When the flow rate of the mobile phase was set at 0.5 mL/
min it was important to set the detector capillary temperature at 350°C. The adjustments 
of these parameters was necessary to maximize the ionization and subsequently the sen-
sitivity of the detector. 
Method validation results
The validation results for linearity, accuracy and precision are demonstrated in Table 
4. For accuracy and precision, the highest overall bias found during the validation was 
11.3% at LLOQ of both lopinavir and saquinavir. The highest overall CV was 15.6% at the 
LLOQ of darunavir. The results for the storage- and freeze-thaw stability are displayed in 
Table 5. Storage stability in a refrigerator (4°C), at room temperature (20 – 25°C) and in 
Table 6. Components analysed in the period from January 2016 until May 2017 for therapeutic drug monitoring (total = 403 
samples). 
Component Number of  samples Median (IQR) concentration (mg/L)
Atazanavir 50 1.4 (0.9-1.9)
Darunavir 142 3.0 (2.1-4.8)
Etravirine 7 0.6 (0.5-0.8)
Lopinavir 65 7.7 (3.9-10.9)
Nevirapine 62 5.6 (3.9-7.2)
Ritonavir 1 3.1#
Raltegravir 75 0.75 (0.2-1.8)
Saquinavir 1 0.5#
#: 1 sample
DASKAPAN A et al.
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the autosampler (10°C) met the requirements with a maximum CV of 13.2% at low QC lev-
el (0.2 mg/L) for saquinavir. Furthermore, freeze-thaw stability was within FDA and EMA 
margins, with a maximum overall bias of 7.4% at low QC level (0.8 mg/L) for tipranavir. 
Selectivity and specificity showed no interfering peaks of more than 20% of the LLOQ. 
For the matrix comparison the integrated peak height ratio of a component and its cor-
responding IS in plasma was compared to that in serum and no statistically significant 
difference between the two matrices was found for each component. Recovery samples 
(LOW, MED, HIGH) were assayed and recovery of all components was higher than 85%, 
with the most deviating recovery of 93.4% at low QC level for etravirine. The dilution integ-
rity was proven with a maximum overall bias of 5% for raltegravir. The carry-over testing 
showed that there was no carry-over. All results of the method validation were within the 
EMA and FDA guidelines.  
 
Clinical application results
This method has successfully been used in clinical practice for TDM in cases of drug-
drug interactions, renal or hepatic morbidities, pregnancy, virologic failure, suspicion of 
nonadherence and adverse events and it was also used in a clinical study on darunavir 
pharmacokinetics [21]. In the period from January 2016 until May 2017 403 plasma sam-
ples were analysed using this bioanalytical method (Table 6). Performance of the assay 
was within the accepted margins (accuracy and precision <20%) of the international 
quality control program of ARV drugs of the KKGT in our laboratory. 
DISCUSSION AND CONCLUSION
The bioanalytical method described here is rapid and simple and provides an efficient 
tool for TDM of ARV drugs. This bioanalytical method contains both new ARVs as older 
ARVs such as tipranavir, saquinavir , indinavir and nelfinavir, making it also suitable for 
resource limited settings were these drugs are currently commonly used. We were struck 
by the good bias and precision data illustrating the robustness of our analysis.
Previously, other comparable assays have been published describing the simultaneous 
determination of PIs, NNRTs and INIs [8, 10, 17, 22]. Three of these studies required a 
time consuming liquid-liquid extraction and did not include stable isotope IS [8, 10, 17], 
what could result in a poorer compensation for inefficiencies in extraction and sample 
preparation steps, as well as for any matrix effect. One of these bioanalytical methods 
contained 17 ARVs, but required liquid-liquid extraction and did not include stable iso-
tope IS [8]. All four of these studies had a relatively long run time varying from 10 – 30 
min. For TDM purposes a relatively small sample volume and simple sample preparation 
is desirable. Therefore, the method described by Kromdijk et al. appears to be the best 
applicable in daily practice compared to the other three methods published [22]. The 
current described bioanalytical method has a shorter run time and includes more ARVs 
which can be determined simultaneously than the study of Kromdijk et al. Due to the sim-
ple sample preparation, which only included  protein precipitation using a precipitation 
reagent, no time-consuming and expensive liquid-liquid extractions and solid-phase ex-
tractions were required. The short run time of 2.9 min, the use of small volumes of plasma 
and the possibility of the simultaneous determination of 14 ARV drugs makes the method 
we described highly suitable for routine service. The currently developed method and the 
applicability for routine service is supported by a recent study by Baldelli et al. [18] where 
a bioanalytical method  for elvitegravir was developed similar to the current one. Baldelli 
et al. utilized the quality by design approach for the method development which entails a 
systematic method for quality standards by looking at the entire development system and 
product life cycle [18]. 
In the current bioanalytical method overlapping retention times of some components were 
demonstrated. For the development of this method we achieved a high resolution on the 
one hand and a fast run-time on the other hand. However, due to its desired applicability 
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for routine service to clinicians, and the high sensitivity and discriminatory power of LC-
MS/MS, a faster run-time prevailed over higher resolution. 
The bioanalytical method was simple, specific, robust, reproducible and demonstrated a 
high sensitivity for all components and better cost-effectiveness than the commonly used 
methods. Our assay platform is suitable for TDM in standard care and in clinical studies 
for old and new ARVs. 
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